BioCryst Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCRX Nasdaq 2830 www.biocryst.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioCryst Pharmaceuticals, Inc.

BioCryst price target raised to $12 from $10 at Evercore ISI - Jan 14th, 2025 1:35 pm
Exploring High Growth Tech Stocks In January 2025 - Jan 10th, 2025 6:06 pm
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - Jan 10th, 2025 12:00 pm
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 12:00 pm
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 6th, 2025 12:00 pm
The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127% - Dec 27th, 2024 10:40 am
High Growth Tech Stocks To Watch In December 2024 - Dec 6th, 2024 6:07 pm
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future - Nov 25th, 2024 4:56 pm
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - Nov 18th, 2024 7:00 am
BioCryst to Present at Upcoming Investor Conferences - Nov 6th, 2024 12:00 pm
BioCryst Announces Strong Q3 2024 Revenue Growth - Nov 5th, 2024 12:29 pm
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Nov 5th, 2024 10:13 am
Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call - Nov 5th, 2024 7:32 am
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... - Nov 5th, 2024 7:03 am
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript - Nov 4th, 2024 7:30 pm
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2024 1:10 pm
BioCryst: Q3 Earnings Snapshot - Nov 4th, 2024 12:06 pm
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 4th, 2024 12:00 pm
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) - Oct 24th, 2024 12:00 pm
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% - Oct 23rd, 2024 1:55 pm